Please login to the form below

Not currently logged in
Email:
Password:

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

Janssen logo 

Johnson & Johnson's Janssen unit has bolstered its hepatitis C virus treatment portfolio with the acquisition of a phase II candidate from GlaxoSmithKline (GSK).

Janssen has taken full ownership of GSK2336805, a once-daily NS5A inhibitor that GSK had advanced into phase II testing for chronic hepatitis C infection in adults with compensated liver disease, including all stages of liver fibrosis.

The company plans to start trials combining GSK2336805 with its non-nucleoside polymerase inhibitor TMC647055 and simeprevir (TMC435) - an NS3/4A protease inhibitor developed with Sweden's Medivir.

"This addition will broaden our clinical development programme as we continue to look for new investigational interferon-free treatment combinations to combat the hepatitis C virus," said Janssen's hepatitis project head Gaston Picchio.

J&J is in a race with a number of other companies to bring an all-oral treatment regimen for hepatitis C to market in order to free patients from the need for injectable and sometimes hard-to-tolerate interferon alfa-based treatment.

Simeprevir has been submitted for regulatory approval in the US, Canada and Europe, and was approved last month in Japan, but a number of other companies are already in the latter phases of development for all-oral hepatitis C regimens.

AbbVie and Gilead Sciences are currently thought to be leading the charge on interferon-free regimens with combination therapies in phase III, although Bristol-Myers Squibb, Boehringer Ingelheim and Merck & Co have also reach the latter stages of testing with their own candidates.

The sheer scale of the hepatitis C virus market in terms of the number of people infected worldwide means it is expected to swell to more than $20bn a year once all-oral regimens hit the market.


Article by
Phil Taylor

9th October 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics